Soike K F, Huang J L, Russell J W, Whiterock V J, Sundeen J E, Stratton L W, Clark J M
Tulane Regional Primate Research Center, Covington, LA 70433.
Antiviral Res. 1994 Apr;23(3-4):219-24. doi: 10.1016/0166-3542(94)90019-1.
A novel nucleoside analog BMS-181165 with potent activity against varicella-zoster virus was tested for efficacy in a simian varicella virus infection in African green monkeys. BMS-181165 was effective in preventing the development of a rash, decreasing the development of viremia and preventing death in infected monkeys when administered orally at 4, 16 or 64 mg/kg/day. The compound is well orally absorbed in monkeys, between 44 to 50% oral bioavailability, and may prove of value in therapy of varicella-zoster infections in humans.
一种对水痘-带状疱疹病毒具有强效活性的新型核苷类似物BMS-181165，在非洲绿猴的猴水痘病毒感染模型中进行了疗效测试。当以4、16或64毫克/千克/天的剂量口服给药时，BMS-181165可有效预防皮疹的出现，减少病毒血症的发生，并防止受感染猴子死亡。该化合物在猴子体内口服吸收良好，口服生物利用度在44%至50%之间，可能对人类水痘-带状疱疹感染的治疗具有价值。
